Treatment of advanced melanoma and ovarian cancer patients with a recombinant fowlpox-NY-ESO-1 vaccine resulted in NY-ESO-1 antibody and CD4+ and CD8+ T-cell responses in the majority of these patients, and CD8+ responses correlated with progression-free survival [91, 92]. Here, CD8A is linked to ovarian carcinoma.